Albertsons posted a loss in the fourth quarter of fiscal 2025 (Q4 FY25), as a charge tied to an opioid settlement framework weighed on results for the period ended 28 February 2026.
The US food and drug retailer said net sales and other revenue for Q4 rose 7.7% from a year earlier to $20.25bn. For the full year, revenue increased 3.5% to $83.17bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In addition, operating performance weakened sharply in the quarter.
Albertsons recorded an operating loss of $506.7m, compared with an operating income of $276m in the same period a year earlier.
For the full fiscal year, operating income declined 52.9% to $727.6m.
The company also moved to a net loss in Q4, reporting a loss of $480.8m versus net income of $171.8m a year earlier.
Full-year net income fell 77.3% to $217.4m.
During the quarter, Albertsons booked a loss of $773.8m, or $599.8m after tax, linked to the opioid settlement framework.
The framework is intended to resolve substantially all opioid-related claims brought or that could be brought against the company by participating states, political subdivisions and Native American tribes, according to the company.
The settlement covers allegations that the retailer’s pharmacies did not adequately monitor and prevent the misuse of prescription opioid medicines.
Albertsons Companies CEO Susan Morris said: “Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong adjusted EBITDA [earnings before interest, taxes, depreciation, and amortisation] despite meaningful top-line pharmacy-related headwinds.
“Across the full year, we remained focused on building a stronger foundation for the future, including investing in our customer value proposition, advancing digital and loyalty, and strengthening the capabilities that support sustainable, long-term growth.”
As of 28 February 2026, Albertsons operated 2,244 retail food and drug stores, including 1,713 in-store pharmacies.
Its estate also included 405 fuel centres, 22 distribution centres and 19 manufacturing sites.
For FY26, the company said it expects identical sales to range from flat to a 1% increase.
It projected adjusted EBITDA of $3.85bn to $3.92bn and adjusted net income per Class A common share of $2.22 to $2.32.
Albertsons plans capital expenditure of $2bn to $2.2bn in FY26.
